- Home
- LANC vs BBIO Comparison
LANC vs BBIO Comparison
Compare LANC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANC
- BBIO
- Stock Information
- Founded
- LANC 1961
- BBIO 2015
- Country
- LANC United States
- BBIO United States
- Employees
- LANC N/A
- BBIO N/A
- Industry
- LANC Packaged Foods
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LANC Consumer Staples
- BBIO Health Care
- Exchange
- LANC Nasdaq
- BBIO Nasdaq
- Market Cap
- LANC N/A
- BBIO 6.7B
- IPO Year
- LANC N/A
- BBIO 2019
- Fundamental
- Price
- LANC $166.84
- BBIO $34.48
- Analyst Decision
- LANC Buy
- BBIO Strong Buy
- Analyst Count
- LANC 4
- BBIO 12
- Target Price
- LANC $209.67
- BBIO $57.09
- AVG Volume (30 Days)
- LANC 222.8K
- BBIO 3.2M
- Earning Date
- LANC 04-30-2025
- BBIO 04-29-2025
- Dividend Yield
- LANC 2.30%
- BBIO N/A
- EPS Growth
- LANC 27.36
- BBIO N/A
- EPS
- LANC 6.15
- BBIO N/A
- Revenue
- LANC $1,886,520,000.00
- BBIO $127,415,000.00
- Revenue This Year
- LANC $5.03
- BBIO $13.67
- Revenue Next Year
- LANC $3.31
- BBIO $118.02
- P/E Ratio
- LANC $26.87
- BBIO N/A
- Revenue Growth
- LANC 0.69
- BBIO N/A
- 52 Week Low
- LANC $156.14
- BBIO $21.62
- 52 Week High
- LANC $202.63
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- LANC 37.40
- BBIO 49.67
- Support Level
- LANC $158.84
- BBIO $33.92
- Resistance Level
- LANC $166.20
- BBIO $39.16
- Average True Range (ATR)
- LANC 4.62
- BBIO 1.43
- MACD
- LANC -2.17
- BBIO -0.16
- Stochastic Oscillator
- LANC 22.20
- BBIO 31.05
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.